The Experts below are selected from a list of 327 Experts worldwide ranked by ideXlab platform

Gideon Koren - One of the best experts on this subject based on the ideXlab platform.

  • Studying the antiemetic effect of vitamin B6 for Morning Sickness: pyridoxine and pyridoxal are prodrugs.
    Journal of clinical pharmacology, 2014
    Co-Authors: Ilan Matok, Shannon Clark, Steve N. Caritis, Menachem Miodovnik, Jason G. Umans, Gary D.v. Hankins, Donald R. Mattison, Gideon Koren
    Abstract:

    Vitamin B6 has been known to possess antiemetic effects since 1942. This water soluble compound has several forms in the circulation including pyridoxine, pyridoxal, and pyridoxal phosphate. The active antiemetic form of vitamin B6 is unknown. This was a pre-specified substudy of a randomized, placebo-controlled trial comparing the antiemetic effect of the doxylamine-vitamin B6 combination (Diclectin®) (n = 131) to placebo (n = 126) in women with nausea and vomiting of pregnancy. Serum concentrations of pyridoxine, pyridoxal, and pyridoxal 5' phosphate (PLP) and doxylamine were measured on Days 4, 8, and 15. With Diclectin® exhibiting a significant antiemetic effect in pregnancy, serum concentrations of pyridoxine were unmeasurable in almost all patients and those of pyridoxal were undetectable in half of patients. In contrast, PLP was measurable at sustained, stable steady-state levels in all patients. Our data suggest that there is a correlation between PLP levels and PUQE score of Morning Sickness symptoms when pyridoxine and pyridoxal levels are undetectable, and hence they might be prodrugs of PLP, which may be the active antiemetic form of vitamin B6.

  • Scary Science: Ondansetron Safety in Pregnancy-Two Opposing Results From the Same Danish Registry.
    Therapeutic drug monitoring, 2014
    Co-Authors: Gideon Koren
    Abstract:

    While perceived safe in pregnancy, several recent studies raise concerns about both fetal and maternal safety of ondansetron. Until more data are available, it should not be a first-line medication for Morning Sickness.

  • treating Morning Sickness prn
    Canadian Family Physician, 2013
    Co-Authors: Gideon Koren
    Abstract:

    Question I received a telephone call from my sister who lives in the United States. She is experiencing moderate symptoms of Morning Sickness, but she tells me that she was advised to treat her symptoms only pro re nata — meaning, when symptoms re-emerge. Does this make sense? Answer No, it does not. Typically, nausea and vomiting of pregnancy continue for weeks and months, and in some cases until labour. It is critical to treat symptoms consistently so the woman can maintain adequate fluid and calorie intake. When symptoms improve, the dose of antiemetic medication should be decreased gradually.

  • the return to the usa of doxylamine pyridoxine delayed release combination diclegis for Morning Sickness a new Morning for american women
    Journal de la thérapeutique des populations et de la pharamcologie clinique, 2013
    Co-Authors: Gideon Koren
    Abstract:

    The US FDA approval in April 2013 of Diclegis®, the doxylamine-pyridoxine combination for Morning Sickness, is a major milestone, particularly since it is indicated for use in pregnancy and the FDA has labeled it a pregnancy category A drug the strongest evidence of fetal safety. After thirty years of being orphaned from an FDA-labeled drug for the most common medical condition in pregnancy, American women and their health care providers have a therapeutic solution that is likely to positively impact millions of women each year. This review highlights the milestones of this antiemetic agent over the last 40 years.

  • Treating Morning Sickness PRN
    Canadian family physician Medecin de famille canadien, 2013
    Co-Authors: Gideon Koren
    Abstract:

    I received a telephone call from my sister who lives in the United States. She is experiencing moderate symptoms of Morning Sickness, but she tells me that she was advised to treat her symptoms only pro re nata- meaning, when symptoms re-emerge. Does this make sense? No, it does not. Typically, nausea and vomiting of pregnancy continue for weeks and months, and in some cases until labour. It is critical to treat symptoms consistently so the woman can maintain adequate fluid and calorie intake. When symptoms improve, the dose of antiemetic medication should be decreased gradually.

G M Booth - One of the best experts on this subject based on the ideXlab platform.

  • traditional tongan cures for Morning Sickness and their mutagenic toxicological evaluations
    Journal of Ethnopharmacology, 2000
    Co-Authors: M Ostraff, K Anitoni, A Nicholson, G M Booth
    Abstract:

    Abstract Every year millions of women become pregnant, and more than 60% of them will develop some form of Morning Sickness. Yet drugs like Thalidomide, Bendectin and other possibly potent teratogens administered for pre-partum nausea have severely limited any medicinal intervention. In Tonga, women have been treated for Morning Sickness for hundreds of years. Two types of traditional treatments exist, the first one consists of an infusion of fresh leaves, commonly called vai momoko. The second type of treatment is called vai haka, which is made from the boiled bark of several trees. In this paper we describe the results of 6 months of intensive interviews in Tonga regarding the second type of treatment called vai haka. In addition, we tested vai haka for mutagenic and teratogenic effects. Data from the Ames TA-98 mutagenic bioassay clearly indicate that vai haka is not mutagenic with or without S-9 activation. Twenty-six experimental CD-1 white mice were gavaged with 0.1 ml of vai haka (at 540×the human dose) while the control group of 17 mice were gavaged with 0.1 ml of water to determine teratogenic and developmental effects of the vai haka. No significant teratogenic or developmental anomalies occurred in the mice dosed with vai haka compared to the controls.

  • Traditional Tongan cures for Morning Sickness and their mutagenic/toxicological evaluations.
    Journal of ethnopharmacology, 2000
    Co-Authors: M Ostraff, K Anitoni, A Nicholson, G M Booth
    Abstract:

    Every year millions of women become pregnant, and more than 60% of them will develop some form of Morning Sickness. Yet drugs like Thalidomide, Bendectin and other possibly potent teratogens administered for pre-partum nausea have severely limited any medicinal intervention. In Tonga, women have been treated for Morning Sickness for hundreds of years. Two types of traditional treatments exist, the first one consists of an infusion of fresh leaves, commonly called vai momoko. The second type of treatment is called vai haka, which is made from the boiled bark of several trees. In this paper we describe the results of 6 months of intensive interviews in Tonga regarding the second type of treatment called vai haka. In addition, we tested vai haka for mutagenic and teratogenic effects. Data from the Ames TA-98 mutagenic bioassay clearly indicate that vai haka is not mutagenic with or without S-9 activation. Twenty-six experimental CD-1 white mice were gavaged with 0.1 ml of vai haka (at 540xthe human dose) while the control group of 17 mice were gavaged with 0.1 ml of water to determine teratogenic and developmental effects of the vai haka. No significant teratogenic or developmental anomalies occurred in the mice dosed with vai haka compared to the controls.

M Ostraff - One of the best experts on this subject based on the ideXlab platform.

  • traditional tongan cures for Morning Sickness and their mutagenic toxicological evaluations
    Journal of Ethnopharmacology, 2000
    Co-Authors: M Ostraff, K Anitoni, A Nicholson, G M Booth
    Abstract:

    Abstract Every year millions of women become pregnant, and more than 60% of them will develop some form of Morning Sickness. Yet drugs like Thalidomide, Bendectin and other possibly potent teratogens administered for pre-partum nausea have severely limited any medicinal intervention. In Tonga, women have been treated for Morning Sickness for hundreds of years. Two types of traditional treatments exist, the first one consists of an infusion of fresh leaves, commonly called vai momoko. The second type of treatment is called vai haka, which is made from the boiled bark of several trees. In this paper we describe the results of 6 months of intensive interviews in Tonga regarding the second type of treatment called vai haka. In addition, we tested vai haka for mutagenic and teratogenic effects. Data from the Ames TA-98 mutagenic bioassay clearly indicate that vai haka is not mutagenic with or without S-9 activation. Twenty-six experimental CD-1 white mice were gavaged with 0.1 ml of vai haka (at 540×the human dose) while the control group of 17 mice were gavaged with 0.1 ml of water to determine teratogenic and developmental effects of the vai haka. No significant teratogenic or developmental anomalies occurred in the mice dosed with vai haka compared to the controls.

  • Traditional Tongan cures for Morning Sickness and their mutagenic/toxicological evaluations.
    Journal of ethnopharmacology, 2000
    Co-Authors: M Ostraff, K Anitoni, A Nicholson, G M Booth
    Abstract:

    Every year millions of women become pregnant, and more than 60% of them will develop some form of Morning Sickness. Yet drugs like Thalidomide, Bendectin and other possibly potent teratogens administered for pre-partum nausea have severely limited any medicinal intervention. In Tonga, women have been treated for Morning Sickness for hundreds of years. Two types of traditional treatments exist, the first one consists of an infusion of fresh leaves, commonly called vai momoko. The second type of treatment is called vai haka, which is made from the boiled bark of several trees. In this paper we describe the results of 6 months of intensive interviews in Tonga regarding the second type of treatment called vai haka. In addition, we tested vai haka for mutagenic and teratogenic effects. Data from the Ames TA-98 mutagenic bioassay clearly indicate that vai haka is not mutagenic with or without S-9 activation. Twenty-six experimental CD-1 white mice were gavaged with 0.1 ml of vai haka (at 540xthe human dose) while the control group of 17 mice were gavaged with 0.1 ml of water to determine teratogenic and developmental effects of the vai haka. No significant teratogenic or developmental anomalies occurred in the mice dosed with vai haka compared to the controls.

Nancy L. Segal - One of the best experts on this subject based on the ideXlab platform.

K Anitoni - One of the best experts on this subject based on the ideXlab platform.

  • traditional tongan cures for Morning Sickness and their mutagenic toxicological evaluations
    Journal of Ethnopharmacology, 2000
    Co-Authors: M Ostraff, K Anitoni, A Nicholson, G M Booth
    Abstract:

    Abstract Every year millions of women become pregnant, and more than 60% of them will develop some form of Morning Sickness. Yet drugs like Thalidomide, Bendectin and other possibly potent teratogens administered for pre-partum nausea have severely limited any medicinal intervention. In Tonga, women have been treated for Morning Sickness for hundreds of years. Two types of traditional treatments exist, the first one consists of an infusion of fresh leaves, commonly called vai momoko. The second type of treatment is called vai haka, which is made from the boiled bark of several trees. In this paper we describe the results of 6 months of intensive interviews in Tonga regarding the second type of treatment called vai haka. In addition, we tested vai haka for mutagenic and teratogenic effects. Data from the Ames TA-98 mutagenic bioassay clearly indicate that vai haka is not mutagenic with or without S-9 activation. Twenty-six experimental CD-1 white mice were gavaged with 0.1 ml of vai haka (at 540×the human dose) while the control group of 17 mice were gavaged with 0.1 ml of water to determine teratogenic and developmental effects of the vai haka. No significant teratogenic or developmental anomalies occurred in the mice dosed with vai haka compared to the controls.

  • Traditional Tongan cures for Morning Sickness and their mutagenic/toxicological evaluations.
    Journal of ethnopharmacology, 2000
    Co-Authors: M Ostraff, K Anitoni, A Nicholson, G M Booth
    Abstract:

    Every year millions of women become pregnant, and more than 60% of them will develop some form of Morning Sickness. Yet drugs like Thalidomide, Bendectin and other possibly potent teratogens administered for pre-partum nausea have severely limited any medicinal intervention. In Tonga, women have been treated for Morning Sickness for hundreds of years. Two types of traditional treatments exist, the first one consists of an infusion of fresh leaves, commonly called vai momoko. The second type of treatment is called vai haka, which is made from the boiled bark of several trees. In this paper we describe the results of 6 months of intensive interviews in Tonga regarding the second type of treatment called vai haka. In addition, we tested vai haka for mutagenic and teratogenic effects. Data from the Ames TA-98 mutagenic bioassay clearly indicate that vai haka is not mutagenic with or without S-9 activation. Twenty-six experimental CD-1 white mice were gavaged with 0.1 ml of vai haka (at 540xthe human dose) while the control group of 17 mice were gavaged with 0.1 ml of water to determine teratogenic and developmental effects of the vai haka. No significant teratogenic or developmental anomalies occurred in the mice dosed with vai haka compared to the controls.